Clinical psychopharmacology of eating disorders: a research update
Hay, Phillipa J., and Claudino, Angélica M. (2012) Clinical psychopharmacology of eating disorders: a research update. International Journal of Neuropsychopharmacology, 15 (2). pp. 209-222.
PDF (Published Version)
- Published Version
Restricted to Repository staff only
The paper presents a critical review (with search date 2010) of the major psychotropic medications assessed in eating disorders, namely antipsychotics, antidepressants, mood-stabilizing medications, anxiolytic and other agents. The evidence of efficacy of drug treatments is mostly weak or moderate. In addition, attrition rates are usually higher than for psychotherapies. However, there is support for use of antidepressants, particularly high-dose fluoxetine in bulimia nervosa, and anticonvulsants (topiramate) for binge-eating disorder. Low-dose antipsychotic medication may be clinically useful as adjunct treatment in acute anorexia, particularly where there is high anxiety and obsessive eating-related ruminations and failure to engage, but more trials are needed. Drug therapies such as topiramate and anti-obesity medication may aid weight loss in obese or overweight patients with binge-eating disorder; however, common or potentially serious adverse effects limit their use.
|Item Type:||Article (Refereed Research - C1)|
|Keywords:||anorexia nervosa, binge eating, bulimia nervosa, treatments|
Angélica M. Claudino has had a conference registration supported by Eli Lilly and has been awarded a prize for Innovative Research which funded conference attendance by Lundbeck.
|Date Deposited:||16 Mar 2012 05:00|
|FoR Codes:||11 MEDICAL AND HEALTH SCIENCES > 1111 Nutrition and Dietetics > 111104 Public Nutrition Intervention @ 100%|
|SEO Codes:||92 HEALTH > 9204 Public Health (excl. Specific Population Health) > 920410 Mental Health @ 100%|
|Citation Count from Web of Science||